RxSight (RXST) News Today $29.60 -0.73 (-2.41%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$29.83 +0.23 (+0.78%) As of 02/21/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period RxSight (RXST) to Release Earnings on WednesdayRxSight (NASDAQ:RXST) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664994)February 19 at 4:44 AM | marketbeat.comStifel Nicolaus Remains a Hold on RxSight (RXST)February 18, 2025 | markets.businessinsider.comBaillie Gifford & Co. Cuts Position in RxSight, Inc. (NASDAQ:RXST)Baillie Gifford & Co. lowered its holdings in RxSight, Inc. (NASDAQ:RXST - Free Report) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 398,907 shares of the company's stock after selling 20,097 shares during the quarter. Baillie GiFebruary 18, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Trading Down 4.7% - Should You Sell?RxSight (NASDAQ:RXST) Stock Price Down 4.7% - What's Next?February 15, 2025 | marketbeat.comBrokerages Set RxSight, Inc. (NASDAQ:RXST) Target Price at $58.13February 13, 2025 | americanbankingnews.comRxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have given a buy recommendFebruary 10, 2025 | marketbeat.comInsider Stock Buying Reaches US$1.83m On RxSightFebruary 2, 2025 | finance.yahoo.comRxSight director sells $108,618 in common stockJanuary 27, 2025 | msn.comShweta Maniar Sells 3,519 Shares of RxSight, Inc. (NASDAQ:RXST) StockRxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Shweta Maniar sold 3,519 shares of the business's stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total value of $108,631.53. Following the completion of the transaction, the director now owns 7,383 shares of the company's stock, valued at $227,913.21. This represents a 32.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.January 27, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Position Reduced by Sara Bay FinancialSara Bay Financial lowered its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 8.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 99,864 shares of the company's stock after selling 8,989 shares during the period. RxSight mJanuary 18, 2025 | marketbeat.comInsider Buying: RxSight, Inc. (NASDAQ:RXST) Director Purchases 1,443 Shares of StockJanuary 18, 2025 | insidertrades.comInsider Buying: RxSight, Inc. (NASDAQ:RXST) Director Buys 1,443 Shares of StockRxSight, Inc. (NASDAQ:RXST - Get Free Report) Director Jesse Anderson Corley purchased 1,443 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $31.18 per share, for a total transaction of $44,992.74. Following the completion of the purchase, the director now directly owns 1,443 shares of the company's stock, valued at approximately $44,992.74. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.January 17, 2025 | marketbeat.comRxSight price target lowered to $43 from $66 at NeedhamJanuary 17, 2025 | markets.businessinsider.comRxSight (NASDAQ:RXST) Shares Down 3.9% - Should You Sell?RxSight (NASDAQ:RXST) Trading Down 3.9% - What's Next?January 16, 2025 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have assigneJanuary 16, 2025 | marketbeat.comRxSight’s Promising Growth Fueled by Strong Market Performance and Strategic ExpansionJanuary 13, 2025 | markets.businessinsider.comRxSight (RXST) Receives a Buy from Bank of America SecuritiesJanuary 13, 2025 | markets.businessinsider.comRxSight (NASDAQ:RXST) Given New $40.00 Price Target at Wells Fargo & CompanyWells Fargo & Company lowered their price target on shares of RxSight from $42.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday.January 13, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Sees Strong Trading Volume - Should You Buy?RxSight (NASDAQ:RXST) Sees Strong Trading Volume - Time to Buy?January 13, 2025 | marketbeat.comStifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $35.00Stifel Nicolaus lowered their price objective on RxSight from $40.00 to $35.00 and set a "hold" rating for the company in a research note on Monday.January 13, 2025 | marketbeat.comRxSight (NASDAQ:RXST) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $66.00 price target on shares of RxSight in a research report on Monday.January 13, 2025 | marketbeat.comBTIG Sticks to Its Buy Rating for RxSight (RXST)January 13, 2025 | markets.businessinsider.comRxSight’s Promising Growth and Profitability Prospects Earn a ‘Buy’ RatingJanuary 13, 2025 | markets.businessinsider.comRxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and ...January 12, 2025 | gurufocus.comRxSight Projects 41% Revenue Growth For Q4January 12, 2025 | markets.businessinsider.comRxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and ...January 12, 2025 | gurufocus.comRxSight, Inc. Reports Strong Preliminary Financial Results for Q4 and Full Year 2024, Provides 2025 Revenue GuidanceJanuary 12, 2025 | quiverquant.comRxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 GuidanceJanuary 12, 2025 | globenewswire.comRxSight (NASDAQ:RXST) Reaches New 12-Month Low - Should You Sell?RxSight (NASDAQ:RXST) Sets New 12-Month Low - Time to Sell?January 10, 2025 | marketbeat.comRxSight, Inc. to Present at the J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comRxSight (NASDAQ:RXST) Hits New 12-Month Low - What's Next?RxSight (NASDAQ:RXST) Reaches New 1-Year Low - Here's What HappenedDecember 30, 2024 | marketbeat.comGeode Capital Management LLC Raises Stock Holdings in RxSight, Inc. (NASDAQ:RXST)Geode Capital Management LLC raised its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 817,117 shares of the company's stock after purchasing an additionalDecember 25, 2024 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Bought by Barclays PLCBarclays PLC boosted its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 389.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,786 shares of the company's stock after purchasing an adDecember 25, 2024 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and six have assignedDecember 22, 2024 | marketbeat.comState Street Corp Boosts Stock Holdings in RxSight, Inc. (NASDAQ:RXST)State Street Corp lifted its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 8.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 817,671 shares of the company's stock after buying anDecember 21, 2024 | marketbeat.comForecasting The Future: 4 Analyst Projections For RxSightDecember 21, 2024 | benzinga.comStifel Downgrades RxSight (RXST)December 21, 2024 | msn.comDo You Believe in the Long-Term Growth Potential of RxSight (RXST)?December 21, 2024 | msn.comRxSight (NASDAQ:RXST) Hits New 52-Week Low - Time to Sell?RxSight (NASDAQ:RXST) Hits New 52-Week Low - Should You Sell?December 20, 2024 | marketbeat.comRxSight (NASDAQ:RXST) Downgraded by Stifel Nicolaus to HoldStifel Nicolaus downgraded RxSight from a "buy" rating to a "hold" rating and decreased their price target for the stock from $65.00 to $40.00 in a report on Friday.December 20, 2024 | marketbeat.comPositive week for RxSight, Inc. (NASDAQ:RXST) institutional investors who lost 1.6% over the past yearDecember 20, 2024 | finance.yahoo.comRxSight (NASDAQ:RXST) Trading Down 0.7% - Here's WhyRxSight (NASDAQ:RXST) Stock Price Down 0.7% - Here's WhyDecember 17, 2024 | marketbeat.comRxSight (NASDAQ:RXST) Trading 3.7% Higher - Here's What HappenedRxSight (NASDAQ:RXST) Trading 3.7% Higher - Still a Buy?December 16, 2024 | marketbeat.comRxSight, Inc. (NASDAQ:RXST) Shares Sold by Lord Abbett & CO. LLCLord Abbett & CO. LLC reduced its holdings in RxSight, Inc. (NASDAQ:RXST - Free Report) by 39.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,049,822 shares of the company's stock after selling 6December 15, 2024 | marketbeat.comRxSight (NASDAQ:RXST) Stock Price Up 1.3% - Should You Buy?RxSight (NASDAQ:RXST) Trading 1.3% Higher - Should You Buy?December 13, 2024 | marketbeat.comRxSight (NASDAQ:RXST) Trading Down 1.6% - Here's What HappenedRxSight (NASDAQ:RXST) Shares Down 1.6% - What's Next?December 12, 2024 | marketbeat.comWells Fargo Downgrades RxSight (RXST)December 12, 2024 | msn.comRxSight downgraded to Equal Weight from Overweight at Wells FargoDecember 11, 2024 | markets.businessinsider.comRxSight (NASDAQ:RXST) Trading Down 4.8% - Should You Sell?RxSight (NASDAQ:RXST) Shares Down 4.8% - Here's What HappenedDecember 11, 2024 | marketbeat.comRxSight (NASDAQ:RXST) Shares Gap Down - Here's WhyRxSight (NASDAQ:RXST) Shares Gap Down - What's Next?December 11, 2024 | marketbeat.com Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Media Mentions By Week RXST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RXST News Sentiment▼0.310.60▲Average Medical News Sentiment RXST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RXST Articles This Week▼45▲RXST Articles Average Week Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inari Medical News Envista News PROCEPT BioRobotics News iRhythm Technologies News Warby Parker News LivaNova News Enovis News NovoCure News TransMedics Group News LeMaitre Vascular News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RXST) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXST Stock Alerts